Tag
A 24-year-old obese male presents with incidental liver abnormalities; imaging reveals severe steatohepatitis with unusual features prompting detailed diagnostic evaluation and management strategies.
The Phase 2b IMPACT trial demonstrates that pemvidutide, a GLP-1/glucagon dual agonist, significantly achieves MASH resolution at 24 weeks without dose titration, though fibrosis improvement did not reach significance at this early timepoin
Waist circumference is a superior predictor of metabolic liver diseases, outperforming BMI and other body metrics in assessing MASLD, MASH, and liver stiffness risks.
Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled
